The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer
Top Cited Papers
- 19 April 2013
- journal article
- research article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 88 (1), 218-230
- https://doi.org/10.1016/j.critrevonc.2013.03.010
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancerClinical and Translational Oncology, 2012
- The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinomaEuropean Journal Of Cancer, 2011
- A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome StudyEuropean Journal Of Cancer, 2011
- Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancerBritish Journal of Cancer, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03European Journal Of Cancer, 2009
- Neutrophil/lymphocyte ratio and its association with survival after complete resection in non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2008
- Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancerBritish Journal of Cancer, 2007
- Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancerJournal of Surgical Oncology, 2005
- The Hallmarks of CancerCell, 2000